Sartorius AG represents a set of values and corporate philosophy focused on innovation, quality, and sustainability. As a leading international laboratory and pharmaceutical equipment provider, Sartorius AG ensures customer satisfaction by continually developing cutting-edge technologies and maintaining the highest standards of product excellence. With a strong commitment to sustainability, the company aims to create long-term value for its stakeholders, including customers, employees, and investors. Sartorius AG's dedication to ethical practices, collaboration, and social responsibility underpins its mission to contribute to the progress of science and the betterment of society.

Sartorius AG, a leading biotechnology and laboratory equipment provider, is primarily present in various countries and regions worldwide. The company's global footprint extends across major markets, including North America, Europe, Asia-Pacific, and Latin America. With its headquarters in Goettingen, Germany, Sartorius AG maintains a strong presence in its home country, serving as a hub for research and production. Moreover, the company has established subsidiaries and offices in key countries such as the United States, China, Japan, France, and many others, enabling Sartorius AG to cater to a diverse customer base and foster strategic collaborations on a global scale.

Sartorius AG, a renowned company in the stock market, has accomplished several significant milestones. With a strong focus on precision and excellence, Sartorius AG has achieved remarkable growth and recognition over the years. Some noteworthy achievements include expanding its global presence by establishing subsidiaries and offices in key markets, continuously innovating and launching breakthrough products, and solidifying strategic partnerships with leading industry players. Sartorius AG has also received prestigious awards for its cutting-edge technology and outstanding performance in the life sciences and biopharmaceutical sectors. Through its dedication to quality and customer satisfaction, Sartorius AG has established itself as a trusted and forward-thinking company in the stock market.

Sartorius AG is a renowned German company with a rich history and background. Founded in 1870, Sartorius specializes in manufacturing and distributing laboratory and process technologies. With a strong focus on biopharmaceutical research and production, the company is widely recognized for its innovative solutions in filtration, weighing, and separation technologies. Sartorius AG has expanded globally and established a strong presence in over 110 countries, catering to a diverse range of industries such as food, healthcare, and biotechnology. With a legacy of excellence, Sartorius AG continues to be a leading provider of cutting-edge scientific instruments and services.

The main competitors of Sartorius AG in the market include Thermo Fisher Scientific, Danaher Corporation, and Merck KGaA.

Sartorius AG is primarily active in the life sciences industry.

The business model of Sartorius AG, a renowned company in the stock market, revolves around providing innovative and high-quality products and solutions for biopharmaceutical research and manufacturing. Sartorius AG specializes in the fields of laboratory instruments, consumables, and services, catering to the needs of pharmaceutical and biotech companies worldwide. With a strong focus on bioprocessing technologies, Sartorius AG enables its customers to efficiently develop and produce medications. Through continuous advancements in technology and a customer-oriented approach, Sartorius AG has established itself as a leading supplier in the life science industry, contributing significantly to the advancement of healthcare.

Sartorius의 P/E 비율은 38.9입니다.

Sartorius의 P/S 비율은 3.54입니다.

Sartorius에 대한 AlleAktien 품질 점수는 4/10입니다.

예상되는 Sartorius 매출은 3.4 조. EUR입니다.

예상되는 Sartorius 이익은 308.86 백만 EUR입니다.

Sartorius AG is a global provider of innovative technologies and solutions for biopharmaceuticals, as well as for laboratory, food, and environmental applications. The company has two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions supplies the necessary technologies and products for the production of biopharmaceuticals, including filtration systems, disposable bioreactors, peristaltic pumps, and process control systems. Lab Products & Services offers innovative laboratory instrumentation and consumables for research, development, quality assurance, and control. The company is known for its use of disposable systems in biopharmaceuticals, which ensure process sterility and reduce cleaning and validation efforts. The company is focused on innovation and customer orientation to remain competitive in a rapidly changing global market. It invests in research and development to offer the most future-proof and efficient technologies and solutions to its customers. Overall, Sartorius operates in a growing industry driven by an increase in global patient data, the rising demand for personalized medicine, and the need for more efficient production processes.

Sartorius은(는) 연간 1번의 배당을 통해 1.25 EUR의 배당금을 지급합니다.

Sartorius는 연간 1번의 배당금을 지급합니다.

Sartorius의 ISIN은 DE0007165607입니다.

Sartorius의 WKN은 716560입니다.

Sartorius의 티커는 SRT.DE입니다.

지난 12개월 동안 Sartorius은(는) 1.43 EUR 의 배당금을 지급했습니다. 이는 약 0.81 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Sartorius은(는) 1.85 EUR의 배당금을 지급할 것으로 예상됩니다.

Sartorius의 현재 배당 수익률은 0.81 %입니다.

Sartorius은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Sartorius은(는) 지난 26년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 1.85 EUR의 배당금이 예상됩니다. 이는 배당수익률 1.05 %에 해당합니다.

Sartorius은 '건강' 섹터에 속합니다.

Sartorius의 마지막 배당금을 0.73 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Sartorius는 1.25 EUR를 배당금으로 지급했습니다.

Sartorius의 배당금은 EUR에 지급됩니다.